Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Receivables (2018 - 2025)

Quantum Biopharma's Receivables history spans 8 years, with the latest figure at $462106.0 for Q4 2025.

  • On a quarterly basis, Receivables fell 38.33% to $462106.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $462106.0, a 38.33% decrease, with the full-year FY2025 number at $462106.0, down 38.33% from a year prior.
  • Receivables hit $462106.0 in Q4 2025 for Quantum Biopharma, down from $749356.0 in the prior quarter.
  • Over the last five years, Receivables for QNTM hit a ceiling of $749356.0 in Q4 2024 and a floor of -$341916.0 in Q2 2021.
  • Historically, Receivables has averaged $289473.0 across 5 years, with a median of $459817.0 in 2023.
  • The widest YoY moves for Receivables: up 166.52% in 2021, down 170.39% in 2021.
  • Tracing QNTM's Receivables over 5 years: stood at $500964.0 in 2021, then skyrocketed by 49.46% to $748754.0 in 2022, then tumbled by 38.89% to $457528.0 in 2023, then skyrocketed by 63.78% to $749356.0 in 2024, then plummeted by 38.33% to $462106.0 in 2025.
  • Business Quant data shows Receivables for QNTM at $462106.0 in Q4 2025, $749356.0 in Q4 2024, and $457528.0 in Q4 2023.